ArticleIn silico pharmacology2025
Molecular modeling to design a multiepitope vaccine against emerging tick-borne Yezo virus and its validation through biophysics techniques.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In silico design and evaluation of a multi-epitope vaccine targeting eyach virus for the prevention of tick-borne encephalitis in humans.Scientific reports · 2026Article
- Solution Structure of Nucleoprotein Domain 1 from the Emerging Yezo Virus.International journal of molecular sciences · 2026Article
- Wedelolactone Inhibits Hepatitis B Virus Replication by Modulating NF-κB and Nrf2/HO-1 Signaling: An in-vitro Huh7 1.3-mer HBV Plasmid Model.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, tickborne orthonairoviruses are regarded as a danger to public health. The new infectious virus known as Yezo virus, which is spread by tick bites, produces a condition marked by fever and a decrease in leucocytes and blood platelets. We suggest a multiepitope vaccination design that makes use of immunoinformatics technologies to combat this new danger. Sequences from Yezo virus proteins were gathered, and they allowed us to identify T-cell and linear B-cell epitopes. The vaccine design showed good physical and chemical characteristics as well as allergenicity and antigenicity. Simulations of molecular docking revealed robust contact with toll-like receptor 4. The HDOCK server generated the docking scores for protein interactions i.e. -295.74 kcal/mol for the epitopes in combined form: -281.98 kcal/mol by the epitopes obtained from nucleoprotein, and epitopes obtained from the glycoprotein shows - 262.67 kcal/mol in response to TLR4. The dynamic analysis of vaccine binding with these receptors was conducted with regards to interaction energetics and complex stability. Results showed that vaccine construct was stable throughout the simulation time intervals with strong hydrogen bonds interactions with TLR4 receptor residues. Lastly, we hypothesize that the vaccination sequence described here has a great chance of eliciting particular and protective immune responses, pending assessment of further experimental investigation. Graphical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.